Bio Rad Laboratories (BIO) Stock Could Be 26% Overvalued Despite Microarray Market Growth

Bio-Rad Laboratories has climbed to about US$372 a share after a mixed stretch of returns, and the key issue now is whether that level makes sense when you line it up against the cash the business is expected to generate. With the stock recovering on a 1 year and year to date basis but still well below where it was 5 years ago, the valuation question hinges on what those cash flows are actually worth today.

• The share price is down 48.7% over 5 years, which puts a lot of weight on whether the current cash flow outlook can support a long term reset in expectations.
• Recent reports highlight Bio-Rad as a leading player across areas like microarray scanners, qPCR instruments, gene silencing tools and recombinant proteins, which can influence how steadily the company converts growth opportunities in life sciences into future cash flows.
• If you'd rather focus on earnings, this one's for you. See what Bio-Rad Laboratories's 44.7x P/E says about the price.

The issue now is whether the current share price is justified by the intrinsic value implied by Bio-Rad Laboratories cash flows under a Discounted Cash Flow (DCF) approach.

If you are weighing Bio-Rad Laboratories on its cash flows and want a broader watchlist built on similar discipline, a focused screen of 29 high quality undervalued stocks can be a useful next step.

Is Bio-Rad Laboratories Getting Expensive on Cash Flow?

The Discounted Cash Flow (DCF) approach here values Bio-Rad Laboratories on the cash it could return to shareholders over time, adjusted back to today. Latest twelve month free cash flow sits at about $325.8 million, so this is a business already generating a solid cash surplus rather than one still burning cash.

Analyst and model projections assume those cash flows keep growing rather than shrinking, with estimates stepping up towards $390 million by 2030 before easing into slower expansion in the following years. Despite Bio-Rad Laboratories being flagged in recent reports as a key player across fast growing niches like microarray scanners and qPCR instruments, the DCF output still puts the estimated intrinsic value meaningfully below the current $372.18 share price. That gap suggests the market is pricing in a richer future than the cash flow model supports right now, and the projected expansion in areas such as genomics and gene silencing helps explain why expectations have been set that high. Find out what Bio-Rad Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.

The Bio-Rad Laboratories Narrative: What Would Justify Today's Price?

Narratives pick up where the Bio-Rad Laboratories valuation puzzle leaves off by spelling out which paths for growth, margins and earnings would need to hold for the shares to be worth significantly more or less than today. Each scenario anchors a fair value to a specific set of potential catalysts and risks, so you can track over time which broad version of Bio-Rad Laboratories' story appears to be taking shape on Simply Wall St's Community page.

Community views on Bio-Rad Laboratories are split between those who see cost efficiency and bioprocess exposure as underappreciated, and those who think guidance cuts and funding risks already cap the upside.

Bull case: roughly fairly valued

"Execution on repeated restructuring, including operating expense, facility and distribution center rationalization and IT and commercial efficiencies that are expected to provide US$30 million to US$35 million of net annual cost savings by the end of 2027, gives Bio-Rad Laboratories an underappreciated opportunity to convert flat or modest revenue changes into higher operating margin and earnings power…"

Discover why this Narrative puts Bio-Rad Laboratories at roughly fairly valued.

Bear case: 33% overvalued

"The current valuation implies that Bio-Rad Laboratories is priced for a smoother recovery in growth and margins than its recent guidance for flat to slightly declining 2026 revenue and 10% to 12% non-GAAP operating margin suggests…"

Explore why this Narrative puts Bio-Rad Laboratories at 33% overvalued.

One more Bio-Rad Laboratories check that belongs next to the cash flow math

Price and cash generation only tell part of the story. The people directing Bio-Rad Laboratories, how they are rewarded and what that encourages them to prioritise, can materially shape what happens next. See who runs Bio-Rad Laboratories and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com